PKX 001
Alternative Names: AAGP; PKX-001Latest Information Update: 28 Jul 2024
Price :
$50 *
At a glance
- Originator Institut National des Sciences Appliquees de Rouen; ProtoKinetix
- Developer ProtoKinetix; University of Alberta
- Class Antihyperglycaemics; Cardiovascular therapies; Eye disorder therapies; Glycopeptides; Glycoproteins; Small molecules
- Mechanism of Action Antioxidants; Free radical scavengers; Selectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Age-related macular degeneration; Cardiovascular disorders; Dry eyes; Type 1 diabetes mellitus
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus in Canada
- 28 Jul 2024 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in Canada
- 28 Jul 2024 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Canada